Related Experiment Video
Updated: Aug 13, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Theranostics for Triple-Negative Breast Cancer
Hyeryeon Choi1, Kwangsoon Kim2
1Department of Surgery, Eulji Medical Center, Eulji University School of Medicine, Seoul 01830, Republic of Korea.
Abstract:
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor prognosis. Current endocrine therapy or anti HER-2 therapy is not available for these patients. Chemotherapeutic treatment response varies among patients due to the disease heterogeneity. To overcome these challenges, theranostics for treating TNBC have been widely investigated. Anticancer material conjugated nanoparticles with target-binding ligand and tracer agents enable simultaneous drug delivery and visualization of the lesion with minimal off-target toxicity. In this review, we summarize recently FDA-approved targeted therapies for TNBC, such as poly-ADP-ribose polymerase (PARP) inhibitors, check point inhibitors, and antibody-drug conjugates. Particularly, novel theranostic approaches including lipid-based, polymer-based, and carbon-based nanocarriers are discussed, which can provide basic overview of nano-therapeutic modalities in TNBC diagnosis and treatment.
Insights
Triple-negative breast cancer (TNBC) lacks targeted treatments. This review explores novel nanocarrier theranostics, including lipid, polymer, and carbon-based systems, for improved TNBC diagnosis and therapy.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis and limited treatment options.
- Current therapies like endocrine or anti-HER2 treatments are ineffective for TNBC.
- Disease heterogeneity leads to variable responses to chemotherapy.
Purpose of the Study:
- To review recently FDA-approved targeted therapies for TNBC.
- To discuss novel theranostic nanocarrier approaches for TNBC diagnosis and treatment.
- To provide an overview of nano-therapeutic modalities in TNBC management.
Main Methods:
- Literature review of FDA-approved targeted therapies for TNBC.
- Exploration of recent advancements in nanocarrier-based theranostics.
- Summary of lipid-based, polymer-based, and carbon-based nanocarrier systems.
Main Results:
- FDA-approved targeted therapies for TNBC include PARP inhibitors, checkpoint inhibitors, and antibody-drug conjugates.
- Nanoparticle-based theranostics offer simultaneous drug delivery and lesion visualization.
- Various nanocarrier platforms show promise for targeted TNBC treatment with reduced toxicity.
Conclusions:
- Targeted therapies and nanotheranostics represent promising strategies to improve TNBC outcomes.
- Nanocarrier-based theranostics enable precise drug delivery and real-time monitoring.
- Further research into nano-therapeutic modalities is crucial for advancing TNBC care.
